Literature DB >> 28264624

Age-Specific IVF Outcomes in Infertile Women With Baseline FSH Levels ≥20 mIU/mL.

Vitaly A Kushnir1,2, Maxie Safdie1, Sarah K Darmon1, David F Albertini1,3,4, David H Barad1,5, Norbert Gleicher1,4,5,6.   

Abstract

INTRODUCTION: Infertile women with severely diminished ovarian reserve who have low birth chances with in vitro fertilization (IVF) are often denied treatment with autologous oocytes. This study was designed to determine age-specific treatment efficacy and clinical characteristics of infertile women with severely diminished ovarian reserve who had live birth following IVF with autologous oocytes.
METHODS: This retrospective cohort study investigated 291 infertile women who underwent 482 IVF cycles with autologous oocytes during 2004 to 2016 at our academically affiliated private fertility center. All women were aged <45 years and had maximum baseline follicle-stimulating hormone (FSH) levels ≥20 mIU/mL. Main outcome measures included pregnancy, spontaneous abortion, and live birth rates. Patient and treatment characteristics were compared for women who achieved a live birth to those who did not.
RESULTS: Live birth rates were 8.6% per treated woman and 6% per started IVF cycle. The spontaneous abortion risk was 27% per clinical pregnancy. Age-specific live birth rates were highest at 17.2% for women <35 years and lowest at 1.9% for women >42 years. Women who achieved live birth were younger than those who did not (38.0 ± 8.0 vs 40.0 ± 6.0; P = .008), had lower FSH levels (25.0 ± 20.0 vs 32.5 ± 31.0; P = .006), and produced more oocytes (3.0 ± 5.0 vs 1.0 ± 2.0; P < .001), as well as transferrable embryos (2.0 ± 2.0 vs 0.0 ± 1.0; P < .001).
CONCLUSION: Infertile women up to 45 years with severely diminished ovarian reserve achieve better live birth rates than previously reported and should not be denied access to IVF based on elevated FSH levels alone.

Entities:  

Keywords:  IVF; diminished ovarian reserve; infertility; live birth rates

Mesh:

Substances:

Year:  2017        PMID: 28264624     DOI: 10.1177/1933719117697130

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  4 in total

Review 1.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

2.  Premature ovarian insufficiency patients with viable embryos derived from autologous oocytes through repeated oocyte retrievals could obtain reasonable cumulative pregnancy outcomes following frozen-embryo transfer.

Authors:  Xiuxian Zhu; Jing Ye; Yonglun Fu
Journal:  Ann Transl Med       Date:  2021-04

3.  In-Vitro Fertilization Outcome Predictors in Women With High Baseline Follicle-Stimulating Hormone Levels: Analysis of Over 1000 Cycles From A Tertiary Center.

Authors:  Gülnaz Sahin; Aysin Akdogan; Murat Hakan Aydın; Mustafa Agah Tekindal; Ege Nazan Tavmergen Göker; Erol Tavmergen
Journal:  JBRA Assist Reprod       Date:  2021-04-27

4.  Which Factors Are Associated With Reproductive Outcomes of DOR Patients in ART Cycles: An Eight-Year Retrospective Study.

Authors:  Lu Li; Bo Sun; Fang Wang; Yile Zhang; Yingpu Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.